Sirtuin activation for diseases of aging and overnutrition
NuSirt Sciences combines established pharmaceuticals and natural products to activate the sirtuin pathway, thereby addressing conditions associated with aging and overnutrition. We target cardiometabolic diseases, including metabolic-associated fatty liver disease (MAFLD), metabolic function-associated steatohepatitis (MASH), obesity, type 2 diabetes, and hypertension.
TRIPLN®
NuSirt is currently developing TRIPLN®, a combination of L-leucine, metformin, and sildenafil.
In addition to animal studies, we have conducted a phase 2 clinical trial with TRIPLN® in MAFLD and MASH, with promising results in severe disease. We also have clinical data a suggesting that TRIPLN® may help manage obesity and lower HbA1c. Based on the latter, we are evaluating TRIPLN® for use in pre-diabetes and type 2 diabetes, where it may provide more comprehensive benefits than metformin alone.
A phase 2 trial of TRIPLN® in hypertension will begin in late 2026, backed by a $2.1 million SBIR grant. Readout will take place in 2027.
LEUSIX®
NuSirt also produces LEUSIX®, a dietary supplement supporting cardiometabolic health and weight management.
In a phase 2 clinical trial of people with obesity, participants who took LEUSIX® and made mild lifestyle changes lost 9% body weight in 6 months. Lean muscle was preserved, suggesting that LEUSIX® could be a supplement or substitute to GLP-1 receptor agonists. Additionally, participants saw decreases in insulin resistance, inflammation, and oxidation.
For more information on LEUSIX®, please visit the NuSirt Health website. You can also follow us on Instagram!